Qilu Pharmaceutical

17 articles about Qilu Pharmaceutical

• Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023

  6/8/2023

  Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706, an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting.

• Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

  5/11/2023

  On May 8, 2023 , the authoritative oncology journal, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706.

• Qilu Pharmaceutical Announces Progress of Clinical Study of QL1706, an Innovative Bifunctional Antibody

  12/29/2022

  In 2022, Qilu Pharmaceutical revealed the latest progress being made with several clinical studies involving its innovative bifunctional antibody, QL1706, at several international and Chinese academic conferences, including the American Association for Cancer Research 2022 Annual Meeting, the American Society of Clinical Oncology 2022 Annual Meeting, the Chinese Society of Clinical Oncology 2022 Annual Meeting, and the European Society for Medical Oncology 2022 Asia Congress.

• Qilu Pharmaceutical Releases Latest Results of QL1604 plus Chemotherapy as First-Line Treatment for Patients with Advanced Cervical Cancer in the Phase II Study at ESMO Asia Congress 2022

  12/4/2022

  Qilu Pharmaceutical announced that the results of the phase II study evaluating QL1604 plus chemotherapy as first-line treatment for patients with recurrent or metastatic cervical cancer were released on 4 December 2022 in oral presentation at the European Society for Medical Oncology Asia Congress 2022.

• Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022

  12/2/2022

  Qilu Pharmaceutical and Active Pharmaceutical Ingredients, announced that the results of the phase II study evaluating QL1706 plus chemotherapy +/- bevacizumab for the treatment of non-small cell lung cancer were released on 2 December 2022 in poster presentations at the European Society for Medical Oncology Asia Congress 2022.

• CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy

  9/26/2022

  CellOrigin Biotech Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- derived Chimeric Antigen Receptor Macrophages for cancer immunotherapy.

• CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop "off-the-shelf" CAR-iMAC cell therapy

  9/5/2022

  CellOrigin Biotech Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary "off-the-shelf" iPSC-derived Chimeric Antigen Receptor Macrophages for cancer immnotherapy.

• Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan

  12/13/2021

  Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan.

• Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China

  7/20/2021

  Sesen Bio announced today that the first patient has been enrolled in China in the clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

• Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical

  6/2/2021

  Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on Tuesday, June 1, 2021 the Company entered into a global supply agreement for Vicineum™ drug substance and drug product with the Company's partner in China, Qilu Pharmaceutical.

• Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application in China for Vicineum™

  3/22/2021

  Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application in China for Vicineum ™ IND approval triggers $3 million milestone payment to Sesen Bio Product market application expected to be submitted to the National Medical Product s Administration in 2022 with potential approval in 2023

• Cend Therapeutics and Qilu Pharmaceutical Announce Partnership

  2/16/2021

  Cend Therapeutics, Inc. , a clinical-stage biotech company, and Qilu Pharmaceutical , a major Chinese pharmaceutical company, announced today that the companies have entered a Collaboration and License Agreement to develop and commercialize Cend’s investigational drug, CEND-1, in Greater China.

• Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™ Accepted for Review by the National Medical Products Administration in China

  1/13/2021

  Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum ™ Accepted for Review by the National Medical Products Administration in China Clinical trial expected to be initiated shortly after NMPA approval of the IND Sesen Bio to receive $3M milestone payment upon IND approval

• Qilu Pharmaceutical and ABEC Continue Large-Scale Bioreactor Partnership

  11/12/2020

  ABEC , a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced Qilu Pharmaceutical Co. has again selected ABEC to rapidly expand production capacity at their cGMP manufacturing facility in Jinan, Shandong, China. ABEC is delivering several sets of large-scale

• Qilu Pharmaceutical Expanding Biopharmaceutical Production Capacity with ABEC Bioreactor Systems

  5/29/2019

  ABEC to supply customized large-scale bioreactor trains to Qilu cGMP manufacturing sites in China

• Qilu Pharmaceutical In-Licenses China Rights To Herceptin Biosimilar From Alteogen

  3/31/2017

• Qilu Pharmaceutical Launches Biosimilar To AstraZeneca PLC's Iressa In China

  2/24/2017